Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLGN 
Collplant Biotechnologies Ltd (CLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: CLGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.46% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.90M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 185106 | Beta 0.86 | 52 Weeks Range 1.40 - 5.48 | Updated Date 06/19/2025 |
52 Weeks Range 1.40 - 5.48 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-05-27 | When Before Market | Estimate -0.04 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -80.2% |
Management Effectiveness
Return on Assets (TTM) -38.34% | Return on Equity (TTM) -75.27% |
Valuation
Trailing PE - | Forward PE 15.55 | Enterprise Value 9289768 | Price to Sales(TTM) 7.23 |
Enterprise Value 9289768 | Price to Sales(TTM) 7.23 | ||
Enterprise Value to Revenue 3.76 | Enterprise Value to EBITDA -5.97 | Shares Outstanding 11454500 | Shares Floating 7651729 |
Shares Outstanding 11454500 | Shares Floating 7651729 | ||
Percent Insiders 10.16 | Percent Institutions 12.23 |
Analyst Ratings
Rating 5 | Target Price 12 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Collplant Biotechnologies Ltd
Company Overview
History and Background
Collplant Biotechnologies Ltd. was founded in 2004 in Israel. It focuses on recombinant human collagen (rhCollagen) based products and technologies for regenerative and aesthetic medicine. Significant milestones include developing and patenting its plant-based rhCollagen technology and advancing products through clinical trials.
Core Business Areas
- Regenerative Medicine: Development of rhCollagen-based products for tissue repair and regeneration, including orthopedic and wound healing applications.
- Aesthetic Medicine: Development of rhCollagen-based products for aesthetic procedures such as dermal fillers.
- Bioprinting: Using rhCollagen as a bioink for 3D bioprinting of tissues and organs.
Leadership and Structure
Yehiel Tal is the Chief Executive Officer. The company has a board of directors and various departments including research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Vertebral Body: rhCollagen-based product currently partnered with Stryker (SYK) for spinal fusion procedures. Stryker holds the exclusive license. Competitors include Medtronic (MDT), Johnson & Johnson (JNJ).
- CollaFill: Dermal filler under development. Competitors include Allergan (ABBV) and Galderma.
- BioInk: rhCollagen bioink for 3D bioprinting. This market is still emerging. Competitors include BICO (formerly CELLINK) and 3D Systems (DDD).
Market Dynamics
Industry Overview
The regenerative medicine market is experiencing significant growth, driven by aging populations and increasing demand for advanced therapies. The aesthetic medicine market is also growing, fueled by consumer desire for minimally invasive cosmetic procedures.
Positioning
Collplant is positioned as a developer of novel rhCollagen-based products. Their competitive advantage lies in the purity and human identity of their rhCollagen, potentially reducing immune response and improving efficacy.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine and aesthetic medicine is estimated to be in the billions of dollars. Collplant is targeting specific segments within these markets, aiming to capture a portion of the market through its proprietary rhCollagen technology.
Upturn SWOT Analysis
Strengths
- Proprietary rhCollagen technology
- Partnership with Stryker
- Potential for improved safety and efficacy compared to animal-derived collagen
Weaknesses
- Limited financial resources
- Reliance on partnerships for commercialization
- Clinical trial and regulatory risks
Opportunities
- Expanding into new therapeutic areas
- Developing new rhCollagen-based products
- Partnering with additional companies
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- MDT
- SYK
- BICO
- DDD
Competitive Landscape
Collplant faces significant competition from larger, more established companies. Its advantage lies in its proprietary rhCollagen technology, which may offer improved safety and efficacy. However, Collplant needs to secure more strategic partnerships and approvals to achieve significant market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on partnership deals and clinical trial progress.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for rhCollagen-based products and expanding partnerships.
Summary
Collplant Biotechnologies is a regenerative medicine company with a focus on recombinant human collagen. Its technology is promising but reliant on clinical trial success and partnerships for commercialization. It is in an emerging market with both big competitors such as Johnson and Johnson and smaller niche market contenders, such as BICO. With the Stryker relationship going well, its future looks promising but needs to be monitored closely for future developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Public News Articles
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual risk tolerance and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collplant Biotechnologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-30 | CEO & Director Mr. Yehiel Tal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://collplant.com |
Full time employees 57 | Website https://collplant.com | ||
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.